Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-07-20
2002-06-04
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253060, C514S256000, C514S275000
Reexamination Certificate
active
06399617
ABSTRACT:
TECHNICAL FIELD
The present invention relates to the use of aryl sulfonamide compounds, active as 5-HT
6
receptor antagonists, in the treatment of obesity.
BACKGROUND ART
Obesity is a condition characterized in an increase in body fat content resulting in excess body weight above accepted norms. Obesity is the most important nutritional disorder in the western world and represents a major health problem in all industrialized countries. This disorder leads to increased mortality due to increased incidences of diseases such as cardiovascular disease, digestive disease, respiratory disease, cancer and NIDDM (type II diabetes). Searching for compounds, which reduce body weight has been going on for many decades. One line of research has been activation of serotonergic systems, either by direct activation of serotonin receptor subtypes or by inhibiting serotonin reuptake. The exact receptor subtype profile required is however not known.
Serotonin (5-hydroxytryptamine or 5-HT), a key transmitter of the peripheral and central nervous system, modulate a wide range of physiological and pathological functions, including anxiety, sleep regulation, aggression, feeding and depression. Multiple serotonin receptor subtypes have been identified and cloned. One of these, the 5-HT
6
receptor, was cloned by several groups in 1993 (M Ruat, E Traiffort, J-M Arrang, J Tardivel-Lacombe, J Diaz, R Leurs, J-C Shwartz.
Biochem. Biophys. Res. Commun
. 1993, 193 (1) 268-276; M Sebben, H Ansanay, J Bockaert, A Dumuis,
NeuroReport
5, 2553-2557 (1994).) This receptor is positively coupled to adenylyl cyclase and displays affinity for antidepressants such as clozapine. Recently, the effect of 5-HT
6
antagonist and 5-HT
6
antisense oligonucleotides to reduce food intake in rats has been reported (J C Bentley, C A Mardsen, A J Sleight and K C Fone Effect of 5-HT
6
antagonist Ro 04-6790 on food consumption in rats traineds to a fixed feeding regime
Br J Pharmac
. 1999 Suppl 126 P66; J C Bentley, A J Sleight, C A Mardsen, K C F Fone 5-HT
6
antisense oligonucleotide ICV affects rat performance in the water maze and feeding
J Psychopharmacol Suppl A
64 1997 255).
Aryl sulfonamide compounds have been disclosed as possessing 5-HT
6
receptor activity and being useful in the treatment of CNS disorders (EP 815861). Further classes of aryl sulfonamide compounds with 5-HT
6
receptor activity have been reported in WO 98/27081 and WO 99/42465. The compounds are believed to be of potential use in the treatment of certain CNS disorders.
The object of the present invention is to present an improved method of treatment of obesity. A further object is a new use of compounds for the manufacture of medicaments for obesity treatment.
REFERENCES:
patent: 5968817 (1999-10-01), Sutcliffe et al.
patent: 6030976 (2000-02-01), Bos et al.
patent: 6060642 (2000-05-01), Tecott et al.
patent: 6316450 (2001-11-01), Bromidge et al.
patent: 0 611 003 (1994-08-01), None
patent: 0 815 861 (1998-01-01), None
patent: 1 072 597 (2001-01-01), None
patent: 11-171856 (1999-06-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/29411 (1998-07-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/42465 (1999-08-01), None
Li et al., 5HT(1A) receptor antagonists enhance. . . , Database Embase, AN:1998058304, abstract, Brain research, Jan. 19, 1998, vol. 781/1-2, pp. 121-128.*
Lemberger et al., Use of specific serotonin uptake inhibitors as antidepressants, Database Embase, AN 86074399., abstract, Clinical neuropharmacology, 1985, vol. 8/4, pp. 299-317.
Caldirola Patrizia
Jossan Sukhwinder
Sakariassen Kjell S.
Svartengren Jan
Biovitrum AB
Fish & Richardson P.C.
Jarvis William R. A.
Kim Vickie
LandOfFree
Use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2965596